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The immune system has two major components, an innate arm and an adaptive arm. Certain autoimmune
diseases of the brain represent examples of disorders where one of these constituents plays a major role.
Some rare autoimmune diseases involve activation of the innate arm and include chronic infantile neurologic,
cutaneous, articular (CINCA) syndrome. In contrast, adaptive immunity is prominent in multiple sclerosis,
neuromyelitis optica, and the paraneoplastic syndromes where highly specific T cell responses and anti-
bodies mediate these diseases. Studies of autoimmune brain disorders have aided in the elucidation of
distinct neuronal roles played by key molecules already well known to immunologists (e.g., complement
and components of the major histocompatibility complex). In parallel, molecules known to neurobiology
and sensory physiology, including toll-like receptors, gamma amino butyric acid and the lens protein alpha
B crystallin, have intriguing and distinct functions in the immune system, where they modulate autoimmunity
directed to the brain.There are extensive interactions between the brain and the
immune system in human autoimmune diseases. This review
focuses on the autoimmune diseases where the brain and spinal
cord itself are attacked. In certain very rare autoimmune
diseases of the nervous system, the more primitive form of
immunity, known as innate immunity, drives the pathology of
autoimmunity. Innate immunity is characterized by a more rapid
response to danger and does not involve antibodies or antigen-
specific receptors on T lymphocytes. Diseases driven through
innate immunity are often triggered in a subcellular compartment
known as the inflammosome, where IL-1 is themain pathological
mediator. These IL-1-mediated autoimmune diseases are epito-
mized by a rare condition called NOMID-CINCA (neonatal onset
multisystem inflammatory disease [NOMID]; chronic infantile
neurologic, cutaneous, articular [CINCA] syndrome) (Church
et al., 2008). However more common conditions, including
Alzheimer’s disease, are likely to involve these same aspects
of innate immunity (Steinman, 2008a). Conversely, a group of
autoimmune diseases of the brain and spinal cord, including
multiple sclerosis, represent situations where adaptive immunity
predominates. Adaptive immunity involves an antigen-specific
T cell and an orchestrated antibody response to a component
of the brain or spinal cord. The major disease in this category
is, first and foremost, multiple sclerosis, where the brain’s white
matter is attacked, and as we are now learning, neurons and
axons are also involved. A rarer form of demyelinating disease,
neuromyelitis optica, where an adaptive immune response is
directed to a water channel, also falls into this category, as do
the paraneoplastic syndromes. In the case of paraneoplastic
syndromes, the adaptive immune responses target cancer anti-
gens that are shared with structures in the nervous system, re-
sulting in some characteristic neurological conditions that often
appear before the clinical presentation of the cancer itself. This
review discusses what is known about interactions betweenthe immune and nervous system in both innate and adaptive
autoimmune brain diseases and highlights how such interactions
inform our understanding about these diseases and their treat-
ment.
Dual Roles of Molecules in Autoimmunity and in Normal
Brain Physiology
The innate and adaptive immune systems involve many mole-
cules that are now known to have dual roles in the immune
system and in normal brain physiology. The ‘‘toll-like’’ receptors
are one of the key families of molecules that convey information
about an impending danger from microbes. They were first
discovered while studying the embryogenesis of Drosophila
(Anderson et al., 1985). Flies that lacked the Toll gene could
not achieve dorsal ventral polarity. A decade later, it was
observed that this same family of genes encoded a product
that conferred resistance to tobacco mosaic virus in plants and
bore resemblance to the cytoplasmic domain of Toll-like recep-
tors in Drosophila and interleukin 1 receptor in mammals
(Whitham et al., 1994). This same family of genes turned out to
have a fundamental role in activating what we now know as
the innate immune system (Medzhitov et al., 1997). It is one of
many remarkable examples of how molecules play a key role
in one context, in this case development, and then play an
entirely different role in another physiological system. This
message about the varied roles of the same molecule in con-
trasting contexts will be repeated throughout this review. And
we will see that many molecules of interest to neurobiologists
and immunologists alike also play fundamental roles in plant
defense mechanisms.
Many of the molecules so well known to immunologists,
including components of the histocompatibility proteins and
elements of the complement cascade which play a major role
in autoimmune diseases of the brain, are now known to playNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 123
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(Boulanger, 2009 [this issue of Neuron]; Deverman and Patter-
son, 2009 [this issue of Neuron], Stevens et al., 2007). Likewise,
molecules that are important in the physiology of the nervous
system or its neurosensory appendages are also keymodulators
of immunity. Such molecules, ranging from alpha B crystallin
(cryab), the major component of the lens of the eye and the first
molecule involved in transduction of visual input, to gamma ami-
nobutyric acid (GABA), the principal inhibitory synaptic trans-
mitter of the nervous system have remarkable roles in the
context of the immune system. Indeed, Cryab and GABA play
large roles in immunity and may account for why the brain and
the eye, whose retina is an out pouching of the brain, have often
been regarded as ‘‘immune privileged,’’ and are quite resistant to
immune attack (Ousman et al., 2007; Bhat et al., 2009).
IL-1, Inflammosomes: Communication between Brain
and Immune System
Fever, triggered via the cytokine interleukin-1, IL-1, is the quin-
tessential manifestation of the brain’s reaction to an immune
danger signal. IL-1 also mediates a group of rare autoimmune
diseases of the brain. Fever, of course, is the most common
manifestation of a fundamental interaction between the brain
and immune system. There is some historical and intellectual
sense of justice, that fever is driven by the first cytokine discov-
ered in the field of immunology. For sure, we all know about fever
from personal experience. Sick days with fever are one of our
most fundamental neurological memories from childhood. IL-1,
the first cytokine that was discovered, exemplifies this class of
molecules that signals danger and alerts the brain. Cytokines,
the fundamental messengers that modulate and tune the
immune response, have potent effects on neurons and glia.
Neurons and glia, like cells of the immune system can produce
many of these key cytokines as well as respond to them (Stein-
man, 2008a; Dinarello and Wolff, 1982).
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Figure 1. The Innate Immune System and
the Brain
The innate immune system is driven by Toll recep-
tors on the cell surface and the inflammosome in
the cytosol. Toll receptors trigger the activation
of NF-kB through a universal adaptor protein
MyD88. An intracellular signaling system acting
through Nod-like receptors consisting in the case
of NALP3 shown here of a pyrin domain (PYR),
a NACHT-like domain, and a NAD domain joined
to leucine-rich repeats, activates caspase 3. Cas-
pase 3 cleaves pro-IL-1 beta produced from
NF-kB activation. The resultant IL-1b triggers
certain autoimmune diseases of the nervous sys-
tem such as CINCA. IL-1 also triggers fever
arriving in the brain through fenestrations in the
blood brain barrier around the hypothalamus.
When Charles Dinarello first cloned
IL-1, he actually had predicted correctly
that it was this cytokine that alerted
hypothalamic neurons of peripheral
danger (Dinarello, 1984). IL-1, like other
cytokines that play key roles in autoim-
mune diseases, such as TNF and IL-6, can breach the blood
brain barrier in the area surrounding the hypothalamus (San-
chez-Alavez et al., 2006; Blatteis, 2007). In addition to anatom-
ical fenestrations in the barrier at this point, there are active
transport mechanisms that allow the entry of these cytokines
to critical neurons in the hypothalamus. These neurons regulate
temperature, sleep, and appetite. We all have experienced the
striking changes that accompany the rise in body temperature
seen with fever. There is loss of appetite and a strong drive to
sleep in the febrile reaction. While not an autoimmune reaction
per se, fever is perhaps the quintessential interaction between
brain and the immune system (Figure 1). IL-1, that same cyto-
kine driving fever, has now been demonstrated to be at the
center of the pathogenesis of a group of rare autoimmune
diseases of the brain, driven by this key constituent of innate
immunity.
The Innate and theAdaptive Armsof the ImmuneSystem
The genes encoding antibodies and T cell receptors employ
elaborate molecular mechanisms for gene rearrangements in
their variable portions to generate a tremendous diversity of
molecules to select and bind virtually any antigen. This is the
fundamental basis of adaptive immunity.
To contrast the innate and adaptive arms of immunity, it must
be emphasized that the adaptive immune system is geared
toward making high-affinity antibodies that bind to antigens
and T cell receptors that recognize antigens bound to shallow
clefts, measuring 10 3 10 3 100 A˚, in a variety of histocompati-
bilty molecules. The process of maturation of a high affinity anti-
body takes weeks, and involves the process of somatic hyper-
mutation of immunoglobulin genes, driven via natural selection
in the regions of the genome encoding the binding sites of these
high-affinity antibodies. The development of a clinically signifi-
cant primary T cell response to an antigen bound to a histocom-
patibility molecule takes a week to 10 days.124 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.
Neuron
ReviewThe action of antibodies and T cell receptors leads to neutral-
ization of the antigen in the case of antibody or destruction of
a cell in the case of a cytotoxic T cell. These cytotoxic T cells
target an antigen bound to a histocompatibility molecule. Both
antibody and T cell receptors, as well as histocompatibility mole-
cules, are members of the immunoglobulin supergene family,
characterized by proteins of about 100 amino acids with a char-
acteristic fold between two antiparallel beta strands. Many
members of the immunoglobulin supergene family including
neural cell adhesion molecules, and major histocompatibility
molecules play roles in shaping neural systems, including ocular
dominance columns in the visual system (Boulanger, 2009;
Hunkapiller and Hood, 1989; Williams, 1992).
The innate immune system in contrast is a more primitive arm
of the immune response and does not depend on gene rear-
rangements–as the adaptive system does—to yield a myriad of
antibodies or T cell receptors of exquisite specificity for each
of billions of potential antigens. Because of this, innate immune
responses can occur much more rapidly than the days to weeks
timescale necessary to launch an adaptive immune response.
For many types of danger, this more immediate immune
response is essential.
The innate immune system has a number of elements in its
repertoire for making powerful and quick responses to danger.
The innate immune system deals with the most urgent problems
requiring an immediate response and does so in a more stereo-
typed way, without tailoring a specific receptor to neutralize the
danger signal in the form of antigen. Instead, in innate immunity
some aspect of the danger signal, often a motif from an infec-
tious microbe, in some cases even a noncoding hexanucleotide
sequence from its genome, a so-called CpG motif, can trigger
a toll-like receptor, the membrane- based sensor of danger
(Sato et al., 1996). In addition, the innate immune system has
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Figure 2. Adaptive versus Innate Immunity
Adaptive immunity features antigen specific
recognition via T cell receptors and immunoglob-
ulin. The T cell receptor (TCR) recognizes antigen
in the cleft of a molecule from the major histocom-
patibility complex (MHC). The innate system has
multiple ways in which it is driven. Besides toll-
like receptors, there are receptors for cytokines,
chemokines, sugars—the mannose receptors, as
well as for the constant region (FC) fragment of im-
munolglobulin. Intracellular signaling via cytokines
goes via JAK and STAT while other receptors acti-
vate NF-kB, culminating in a cascade of inflamma-
tory mediators including cytokines.
a cytosolic system to sense danger, the
Nod-like receptors or NLRs. An intracel-
lular system, the inflammosome is where
signals between the TLR system and the
NLR system are integrated. The major
currency of the inflammosome is the
cytokine, interleukin-1 (Church et al.,
2008; Lamkanfi and Dixit, 2009; Martinon
et al., 2009; Figure 2).
Once the toll-like receptor is triggered,
cytokines complement and other rapid-
acting mediators are produced, primarily in polymorphonuclear
leukocytes, macrophages, and dendritic cells within the immune
system, as well as glial cells within the brain. The NLR system
when inappropriately triggered culminates in a group of rare
but fascinating autoimmune diseases, including some involving
the brain. Thus, the innate immune system is tuned to respond
immediately to danger signals ranging from small molecules
like urate deposited in the joints in gout, to peptidoglycans in
the cell walls of pathogenic bacteria in septic shock (Martinon
et al., 2009).
Autoimmune Diseases of Brain Involving Innate
Immunity and IL-1
The inflammosome is organized tomodulate the secretion of IL-1
in response to real danger or to ‘‘perceived’’ danger. Autoim-
mune diseases driven by the inflammosome are likely the result
of a mistaken immune response to a perceived danger signal,
probably of a microbial nature. These diseases include some
that involve the brain. Autoimmune diseases of the inflammo-
some include Blau syndrome (with granulomatous arthritis, iritis,
and skin rash), familial cold autoinflammatory syndrome (FCAS),
Muckle-Wells syndrome (MWS), pyogenic sterile arthritis with
pyoderma gangrenosum (PAPA), and chronic infantile neurol-
ogical cutanaeous and articular syndrome also known as
neonatal-onset multisystem inflammatory disease, CINCA/
NOMID (Church et al., 2008).
The inflammosome has an interesting association with one of
the degenerative neurological diseases, spinal muscular
atrophy, where the anterior horn cells in the spinal cord control-
ling motor neurons degenerate. In humans, there are 22 NLR
family members including five members of the NOD family
(nucleotide-binding oligomerization domain), 14 NALPs, IPAF
(IL-1B-conversting enzyme protease activating factor), NAIPNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 125
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patibility complex class II transactivator) (Church et al., 2008).
NAIP is partially deleted in children with spinal muscular atrophy,
a neurodegenerative disease affecting the anterior horn cell, with
many features of amyotrophic lateral sclerosis, the quintessen-
tial motor neuron disease (Liston et al., 1996). NAIP gene deletion
is correlated with a more severe phenotype in SMA (Gendron
and MacKenzie, 1999). CIITA, another key component of the in-
flammosome, is amaster regulator of class II major histocompat-
ibility expression. Certain mutations of CIITA are associated with
profound immune deficiency (Dziembowska et al., 2002).
The core of the inflammosome contains a pyrin domain, a cas-
pase recruitment domain (CARD), and an intermediary nucleo-
tide-binding domain (NBD; NACHT or NAD); and a C-terminal
LRR (leucine-rich repeat) (Church et al., 2008). Mutations in the
NACHT domain of NALP3 are linked to CINCA/NOMID, FCAS,
andMWS [Church et al., 2008]. Manifestations of CINCA/NOMID
begin in the neonatal period. Clinically, manifestations of CINCA/
NOMID include urticaria, skin rashes with ‘‘hive’’-like features,
fevers, and recurrent meningitis. Elevated intracranial pressure,
hearing loss, seizures, and delayed and impaired neurological
development ensue. Visual loss occurs from increased intracra-
nial pressure. The increased pressure and chronic inflammation
lead to brain atrophy. Sixty percent of patients have amutation in
the cold-induced autoinflammatory syndrome (CIAS1) gene
(Church et al., 2008; Neven et al., 2004). Because of thismutation
in the inflammosome involving a cryopyrin, caspase 1 activity is
not regulated. Therefore, IL-1 activity in brain increases. The IL-1
receptor antagonist, Anakinra, has produced dramatic improve-
ment in patients with CINCA/NOMID with amelioration of
seizures and meningitis. Clinical improvement is dramatic after
administration of Anakinra, with cessation of seizures and
marked improvement in neurological deficits (Hedrich et al.,
2008).
While CINCA/NOMID is a rare condition, the inflammosome
may play a vital role in the major degenerative disease of the
central nervous system, Alzheimer’s. As reviewed in detail
recently (Lucin and Wyss-Coray, 2009 [this issue of Neuron];
Steinman, 2008a), Alzheimer’s disease has all the hallmarks of
involvement of the innate aspect of the immune system. There
is, however, no infiltration of B cells producing antibodies or
T cells in the Alzheimer’s brain. Instead, there is evidence of acti-
vation of other components of the immune system including
complement, interleukin 1 alpha and beta, and other cytokines
including tumor necrosis factor TNF and transforming growth
factor beta (Griffin et al., 1989; Wyss-Coray, 2006). Complement
of course has recently been shown to play a key role in synaptic
elimination (Stevens et al., 2007). Whether its more traditional
role as an opsonin is at play in the brain of Alzheimer’s disease
remains an open question. Other elements of innate immunity
including the cytokine TGF play a role in AD. Activation of TGF
beta in microglial cells was associated with increased clearance
of beta amyloid, which is the center of great attention in research
on AD (Wyss-Coray, 2006; Steinman, 2008a).
Still, the greatest amount of attention in Alzheimer’s is focused
on beta amyloid. Mutations in amyloid precursor protein and in
presenilin genes encoding proteins involved in processing
amyloid are associated with early onset and familial AD126 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.(Wyss-Coray, 2006). Beta amyloid itself is a danger signal capable
of triggering the innate immune system (Salminen et al., 2009).
In summary, from its role in rare diseases like CINCA/NOMID
to its potential role in the most prevalent neurological disease
in adults, Alzheimer’s, the innate immune system without
accompaniment from the adaptive immune has prominence in
a swathe of neurological diseases.
Autoimmunity in Brain Characterized by an Adaptive
Immune Response
Multiple sclerosis affects about 1.5 million people worldwide.
The disease is characterized in the majority of cases by a period
of relapses and remissions. The relapses affect various aspects
of the nervous system depending on the anatomical location of
the attack. Visual, motor, sensory, and autonomic deficits all
occur. The period of attack is often followed by a remarkable
amount of recovery and a long period of quiescence of disease
termed remission. Some of the keymolecules involved in relapse
and remission, including alpha-4 integrin, osteopontin, and alpha
B crystallin, have been recently described in a review (Steinman,
2009a). About a third of patients progress within a decade or two
fromdisease onset to a form ofMS called secondary progressive
disease, where relapses and remissions are not prominent. In
secondary progressive MS, the disease with its accompanying
neurological disability progresses insidiously.
In multiple sclerosis, there is a strong imprimatur of an adap-
tive immune response. Within the central nervous system CD4,
CD8, and NKT cells are found along with B cells (Goverman,
2009). Perivascular cuffs of lymphocytes are found particularly
in the white matter in acute lesions. Among the most prevalent
proteins found in the affected lesions are immunoglobulins. In
fact, within the central nervous system of MS patients, there is
a net synthesis of immunoglobulin, above and beyond what is
made outside the nervous system. This measurement of immu-
noglobulin synthesis within the brain compartment was at one
time a key confirmatory measurement to confirm the diagnosis
of multiple sclerosis. Such measurements are still valid, but
one usually relies on magnetic resonance imaging for confirma-
tion of clinical diagnosis (McFarland and Martin, 2007).
Antibodies are found in the cerebrospinal fluid with specific-
ities for all the major myelin proteins and many of the myelin
lipids. On electrophoresis there is evidence of restricted clonality
of the immunoglobulin response. Sequencing of immunoglobulin
gene rearrangements in the central nervous system (CNS)
demonstrates that there are clonally derived responses. Disrup-
ted myelin is often associated with deposits of immunoglobulin
and activated complement (Scolding et al., 1989). The specificity
of these oligoclonal immunoglobulin responses remains enig-
matic. Similarly, at the T cell level there are CD4, CD8, and NK
T cells with specificity for the major myelin proteins, and some
of the myelin lipids. Similar to the restricted clonality of certain
immunoglobulin sequences in MS brain (Obermeier et al.,
2008; Lambracht-Washington et al., 2007), one can also demon-
strate restricted clonality of certain T cell responses. Some of
these clonally restricted T cells have specificity for myelin
proteins (Oksenberg et al., 1993; Babbe et al., 2000).
The two major elements of adaptive immunity produce toxic
mediators and in turn interact with other inflammatorymediators.
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Figure 3. Comparison of Innate and
Adaptive Autoimmunity in Brain
In CINCA, IL-1 is activated leading to fever, menin-
gitis, seizures, visual and hearing loss, increased
intracranial pressure, delayed neurological devel-
opment, and brain atrophy. All this is reversed by
administration of IL-1 receptor antagonist, the
drug anakinra. In contrast, in multiple sclerosis
there are perivascular infiltrations of T cells, B
cells, and macrophages. Microglia are activated
as well. Oligoclonal nests of T cells with restricted
diversity in their T cell receptors (TCRs) found in
brain, and oligoclonal immunoglobulins (Ig) are
found in the cerebrospinal fluid. In MS, some of
these restricted responses are directed to known
components of the myelin sheath. In the paraneo-
plastic syndromes, the adaptive immune response
targets cancer antigens that are shared by various
structures in the central nervous system. In neuro-
myelitis optica, the aquaporin 4 (Aqp4) water
channel is targeted by the adaptive immune
response.Immunoglobulins interact with complement via their Fc recep-
tors. One can find a set of complement proteins, membrane
attack complexes, in the spinal fluid. These complexes are prima
facie evidence of immune damage to critical oligodendrocyte
membranes (Scolding et al., 1989). T cells and their accompa-
nying presenting cells produce a long list of proinflammatory
cytokines, chemokines, and other cytokine-like molecules
(Figure 3).
There is hot debate about whether so-called TH1 or TH17
cytokines mediate brain inflammation (Bettelli et al., 2007;
Tzartos et al., 2008; Kebir et al., 2007; Steinman, 2008b). What
is certain is that the hallmark cytokine of TH1, gamma interferon,
when given toMSpatients induced disease (Panitch et al., 1987).
Another molecule, osteopontin, modulates both TH1 and TH17
and is found to be elevated during relapse. Osteopontin is
a member of a family of small integrin binding proteins, the
SIBLING family. Osteopontin binds a4b1 integrin (reviewed in
Steinman, 2009a). This integrin is critical in migration of lympho-
cytes to the brain in MS. Blockade of a4b1 integrin with a mono-
clonal antibody approved for treatment of relapsing remitting
MS, called Natalizumab, reduces relapses by two-thirds (Polman
et al., 2006). This reduction in the relapse rate comeswith a price,
for blockade of homing to the brain carries with it the risk of fatal
infection with dormant viruses in the brain with a disease called
progressive multifocal leukoencpephalopathy (reviewed in
Steinman, 2009a).
At present, there is great controversy about what triggers MS.
Some argue that a microbe somehow induces MS. Others argue
that some degenerative, biochemical disturbance is a possibility.
After all, in X-linked adrenoleukodystrophy (ALD), there is
a primary biochemical disturbance in brain caused by amutation
in an ABC transporter. This biochemical abnormality subse-
quently elicits an inflammatory lymphocytic infiltrate in brain,
a pathology reminiscent of MS, but a picture quite different
than what is seen in AD for example (Mosser et al., 1993). Soin principle, mutations in biochemical pathways in the nervous
system may underlie an inflammatory demyelinating condition
likeMS, just as it does in ALD. So far, however, there is not a great
deal of evidence to support this contention. One piece of
evidence that does exist came from studies on MS brain lesions.
Abnormalities in fumarate metabolism have been noted in MS
lesions, with increased transcription of fumarylacetoacetate
hydrolase in both acute and chronic lesions of MS (Lock et al.,
2002). Fumarate esters have shown promise in early stage clin-
ical trials of MS (Kappos et al., 2008).
Other possibilities have also been hinted at from various
research studies. An intriguing report showed that in the earliest
pathological lesions there is no evidence of lymphocytic infiltra-
tion, instead extensive apoptosis in oligodendroglial cells and
activation of microglia were observed. The apoptotic oligoden-
drocytes might be the trigger of the adaptive immune response
(Barnett and Prineas, 2004). Another possibility is a microbial
infection of brain, with subsequent bystander damage to neigh-
boring brain structures (Steinman and Oldstone, 1997), though
searches for microbes triggering MS have been altogether
unsuccessful. Spurts of enthusiasm for one or another potential
culprit continue to appear, and currently EBV is the microbe elic-
iting the most enthusiasm based on some tantalizing data (Ser-
afini et al., 2007). There is also the potential possibility that the
underlying trigger for MS stems from the astonishing mimicry
between components of a variety of common microbes and
constituents of the myelin sheath and even neurons, suggesting
that MS may be an inappropriate ‘‘auto’’-antibody response. In
one of the most intensively studied examples, attention has
been focused on the motif of four amino acids HFFK. These
four amino acids include themain anchors to both a hydrophobic
pocket in the class II HLA molecule HLA DR2, and the primary
contact with both the T cell receptors and immunoglobulins
that recognize a particular dominant immunogenic region of
MBP, between residues 82 and 98 (Wucherpfennig et al.,Neuron 64, October 15, 2009 ª2009 Elsevier Inc. 127
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between other viruses like Hepatitis B and myelin oligodendrog-
lial glycoprotein, and Hepatitis A viral polymerase and myelin
basic protein (Fujinami and Oldstone, 1985).
Despite the attraction of these molecular similarities between
microbes and components of the myelin sheath, no single
microbe has been impugned in the pathogenesis of MS. In
contrast, in the inflammatory polyneuropathy known as Guillain
Barre syndrome, Campylobacter jejuni has been implicated as
the trigger for acute axonal motor neuropathy, a type of inflam-
matory neuropathy resembling Guillain Barre. Campylobacter
jejuni contains glycolipids that are also found in motor axons
(Hao et al., 1998). Immune attack against these glycolipids trig-
gers acute motor axon neuropathy.
While it may be debated what actually causes MS, the pres-
ence of the adaptive immune response is widespread in MS.
Adaptive immunity is evident both in acute lesions of MS and
even in more active chronic lesions of MS. This has been shown
indisputably with a number of histological, immunological,
molecular, and proteomic technologies. While current approved
treatments for MS either target innate immunity via beta inter-
feron or glatiramer acetate or block homing of lymphocytes to
the inflamed brain via a4 integrin blockade (Polman et al., 2006;
Steinman, 2009a), alternative approaches aimed at adaptive
immunity are promising. Tolerizing the adaptive immune system
to myelin antigens is one such promising approach. It has been
demonstrated in a phase II clinical trial that tolerizing the immune
system to myelin basic protein reduces antibodies to this myelin
component that are detectable in the spinal fluid. Tolerization to
myelin basic protein was accompanied by a reduction in
magnetic resonance lesions indicative of brain inflammation in
patients with relapsing remitting MS (Garren et al., 2008).
Furthermore, recently it has been shown that not only is white
matter targeted in MS, but gray matter is affected, resulting in
cognitive disturbances and ultimately brain atrophy (Geurts
et al., 2009; Han et al., 2008). Some of the targets of adaptive
immunity involving gray matter have recently been described.
Among the targets is contactin-2, which is located at the node
of Ranvier, a critical location in the myelinated axon, where
conduction of the electrical impulse, known as the action poten-
tial, actually cycles inward to depolarize the neuronal membrane.
Thenodesare locatedbetweenstretchesofmyelinated, insulated
axon (Derfuss et al., 2009; Steinman, 2009b). Tolerizing the adap-
tive immune system so that it does not produce antibodies and
pathological T cell responses to these gray matter targets, espe-
cially those at the Node of Ranvier, warrants exploration.
Multiple Sclerosis Exemplifies Dual Roles of Key
Molecules in Brain Autoimmunity and in Neurobiology
The mechanism of control of relapse and induction of remission
bring together one of the more interesting intersections in our
understanding of the brain and the immune system. It has long
been contended that certain anatomical locations in the body
have immune privilege. These are regions where it is extremely
difficult to induce inflammation. They include the brain, the testis,
the gravid uterus, and the lens of the eye. In these sites, trans-
plants are unlikely to be rejected. Interestingly, in these fetal
tissues, small heat shock proteins (sHSPs) of the crystallin family128 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.including aB crystallin are also increased in expression. These
sHSPs have played important roles all through evolution. They
play key roles in the defense of plants against a variety of path-
ogenic and metabolic stresses (Maimbo et al., 2007). aB crystal-
lin is also known to inhibit inflammation and apoptosis via inhibi-
tion of p38 map kinase and cleavage of caspase 3, respectively.
In acute multiple sclerosis lesions, expression of aB crystallin is
dramatically increased and, in animal models of MS, administra-
tion of aB crystallin dramatically induces remission and reverses
ongoing paralytic disease. It is remarkable that the major struc-
tural protein of the lens of the eye, so well known in its role for re-
fracting light, is also a remarkable guardian molecule protecting
the brain and other vital tissues from undesired inflammatory
responses (Ousman et al., 2007; Ransohoff, 2007). Members
of this sHSP family also play a potential role in a variety of brain
diseases beyond MS, including Alzheimer’s disease, stroke,
Alexander’s disease, caused by amutation in glial fibrillary acidic
protein, and Parkinson’s disease (Steinman, 2009a).
The nervous system responds to inflammatory stress by also
inducing a spectrum of beta interferon-induced mediators
(Han et al., 2008). Beta interferon itself is highly anti-inflammatory
and is the most widely used form of therapy for relapsing remit-
ting MS. Though other forms of therapy like blockade of a4b1 in-
tegrin are more efficacious then beta interferon, they carry the
large risk of immune suppression within the brain. To date, 13
cases of progressive multifocal leukoencephalopathy have
been reported in the first 50,000 patients under therapy. The
majority of these cases occur after blockade of the a4b1 integrin
for a year or more (Steinman, 2009a).
Examination of databases of proteomic and transcriptomic
analyses of well-defined lesions in MS brains indicates that the
brain’s GABAergic inhibitory system is modulated in active and
chronic lesions in MS (Han et al., 2008; Lock et al., 2002; Tajouri
et al., 2003; Dutta and Trapp, 2007). GAD (glutamic acid decar-
boxylase, the enzyme that synthesizes GABA), GABA receptor
subunits and associated proteins, and a GAT (GABA reuptake
transporter) are altered inMS, both at the level of gene transcripts
andprotein expression (Lock et al., 2002;Han et al., 2008). Exam-
ination of gene transcripts in lesions from MS brains indicates
that GAD is decreased in both acute and chronic lesions, and
various GABA-receptor subunits are either increased or
decreased in the lesions (Lock et al., 2002; Tajouri et al., 2003).
Transcripts for GABA-A receptor subunit g2, for example,
increase in acute plaque but decrease in chronic active plaque.
GABA-A receptors are chloride channels formedby heteropenta-
meric assemblies of these subunits with subunit composition
determining receptor specificity and other aspects of receptor
function. The g2 subunit is involved with GABA-A receptor traf-
ficking and synaptic clustering. Thus, these subunit alterations
in MSmay lead to functional changes in the receptors and signal
transfer. In chronic MS lesions in motor cortex, GAD, various
GABA receptor subunits, and GABA receptor associated protein
(GABRAP) are all decreased (Dutta and Trapp, 2007). At the level
of protein expression, GAD andGAT1 are increased in acute pla-
que and GABRAP is increased in chronic plaque (Han et al.,
2008). The reasons underlying these differences in transcrip-
tomic versus proteomic data represent aspects of active regula-
tory processes. Furthermore, the implications of these findings
Neuron
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(EAE), a mouse model of MS in use for over 75 years. A compar-
ison of levels of GAD, GABA transaminase (GABAT, the enzyme
that degrades GABA), and various GABA receptor subunits
showed significant decreases in the spinal cord of these gene
transcripts in the first acute phase of EAE (Bhat et al., 2007).
When these data are considered together, such findings indicate
that the GABA system is pathologically regulated in MS brains.
The dysregulation of molecules in the GABA pathway in
human MS and in EAE could be a cause, consequence, or just
a correlation with the disease process. To begin to address
this, the GABA system has been manipulated by specifically
increasing GABAergic activity in EAE. When topiramate, a
GABA receptor type A agonist, is administered, there is an
increase in GABA-mediated signaling. When vigabatrin, an irre-
versible blocker of GABAT, GABA transaminase, the main
enzyme that degrades GABA, there is a decrease in GABA
degradation. This causes an effective increase in systemic
GABA concentrations. Both these agents greatly reduce the inci-
dence and severity of paralysis in EAE in mice immunized with
a myelin peptide when started at the time of immunization.
This demonstrates that these agents inhibit the development of
acute EAE including the paralysis of the arms and legs that
accompanies the experimental disease. These pharmaceuticals
also reverse paralysis significantly when given after establish-
ment of disease. These effects were in part due to direct signif-
icant inhibition of immune cells through GABA-A receptors (Bhat
et al., 2007, 2009) Since levels of GABA are decreased in serum
of MS patients (Demakova et al., 2003), this GABA effect on
peripheral immune cells may also be important in human MS.
GABA in the CNS is synthesized and utilized by neurons and
glia through GABA receptors and reuptake transporters, and
GABA is present in both gray and white matter (Jensen et al.,
2005; Choi et al., 2006). There is recent evidence of significant
GABA release in white matter with subsequent high-affinity
uptake and catabolism (Henjum and Hassel, 2007). In injured
white matter, there may be an upregulation of GABA receptors
and accordingly, it was postulated that GABA receptor expres-
sion in whitematter may be protective during hypoxia in the adult
and in the developing brain (Henjum and Hassel, 2007). GABA is
also produced and secreted by immune cells (Bhat et al., 2009).
White matter lesions in MS are typically characterized by signif-
icant immune cell infiltration. Thus, within white matter lesions of
MS as well, this neurotransmitter may be performing dual roles in
both inhibition of inflammation and prevention of nerve injury and
crosstalk between the cells of the nervous and immune systems.
The biochemical pathways associated with GABA, like those
associated with the small heat-shock proteins, are part of an
ancient physiological system. The GABA pathways are present
in plants where they serve to protect against various types of
stress including heat (Taiz and Zeiger, 2006). The GABA path-
ways restrict levels of reactive oxygen intermediates in plants
(Bouche et al., 2003). The known function of GABA as an inhibi-
tory transmitter in the nervous system is paralleled by a role in the
immune systemwhere it guards against dangerous inflammation
in sensitive tissues like the brain.
The role of MHC in susceptibility to MS is another area where
there is an interesting intersection between neurobiology andimmunology. For the past 35 years, it has been well known
that the major gene conferring a risk of susceptibility to MS
resides in the major histocompatibility complex. Recent studies
have pinpointed the HLA DRB1*1501 gene as the main suscep-
tibility allele (Fugger et al., 2009). Other susceptibility loci within
the HLA class I and II region may modify the effect of HLA
DRB1*1501 by acting in trans. The pioneering studies of Shatz
and colleagues have indicated that the role of MHC genes is
not always in simply providing the appropriate protein molecule
for presenting antigen to T cell receptors. Shatz and colleagues
have shown that the development of the visual system is altered
in mice with deficient MHC class I expression (Huh et al., 2000;
Boulanger and Shatz, 2004). There is failure of segregation of
ipsilateral and contralateral connections in the lateral geniculate
projections of retinal ganglion cells in mice with deficient expres-
sion of MHC class I. In these MHC class I deficient mice there
was enhancement of long term potentiation in the hippocampus,
while long term depression was absent.
Clearly, the MHC has dramatic effects on the anatomy and
physiology of neurological synapses.MHC class I leads to weak-
ening and structural retraction of synaptic connections. Remark-
ably the GABA system has an opposite effect on synaptic plas-
ticity. Mice with glutatmic acid decarboxylase 65 knocked out,
deficient in GABA, show absence in the plasticity of ocular domi-
nance columns, with inability to shift dominance to the more
active eye. The GAD65 knockout mice have diminished GABA
release, and this translates into alteration of NMDA excitatory
transmission. These effects in the GABA knockout are restored
by adding a critical amount of excitatory transmission through
NR2A-containing NMDA receptors (Kanold et al., 2009). Thus,
there are fine tuned and intertwined regulatory mechanisms for
synaptic plasticity involving MHC class I molecules, their recep-
tors like the Paired-immunoglobulin-like receptor B (PirB), the
GABA system and NMDA transmission (Atwal et al., 2008).
Clearly the roles of MHC and GABA extend from the nervous
system to the immune system. The underlying mechanisms
however may be quite different and fascinating.
Other Adaptive Immune Disorders
An adaptive immune response to aquaporin 4 underlies an
unusual chronic demyelinating condition, termed neuromyelitis
optica. As the name of the condition anticipates, the optic nerve
and spinal cord are involved in the typical form of NMO. Anti-
bodies play a key role in its pathogenesis as shown with the
following evidence: (1) gammaglobulin and complement deposi-
tion are present in spinal cord lesions, (2) attacks, which occur
muchmore frequently than relapses in MS, respond to treatment
with plasmapharesis, whereas MS does not improve with plas-
mapheresis, and (3) an auto-antibody (NMO-IgG) directed
against aquaporin 4 (AQP4) distinguishes NMO from multiple
sclerosis, where such antibodies are not detected. Finally, (4)
AQP4 is lost in acute lesions in the spinal cord in acute NMO
(Lennon et al., 2005; Hinson et al., 2008). These findings empha-
size a pathological role for NMO-IgG in this demyelinating
disorder of the central nervous system.
One of the more fascinating examples of adaptive immunity
driving an autoimmune disease occurs at the interface of cancer
and the immune response in what we call ‘‘tumor surveillance.’’Neuron 64, October 15, 2009 ª2009 Elsevier Inc. 129
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body and T cell response directed to a shared antigen expressed
on a solid tumor and on a component of the central nervous
system. Thus, in the course of ‘‘tumor surveillance’’ an autoim-
mune disease in the nervous system is instigated. The most
common example of a paraneoplastic syndrome is the cerebellar
syndrome, where clinical findings include ataxia and tremor so
severe that even handwriting is often impaired, in some individ-
uals with ovarian cancer. The antigen expressed on the ovarian
cancer is also expressed on Purkinje cells in the cerebellum.
Often the neurological disorder becomes apparent before there
is any diagnosis of malignancy (Darnell and Posner, 2006). The
immune systemmounts an adaptive response to a protein called
cdr2, and the antibodies are often termed anti-Yo antibodies.
Other forms of paraneoplastic cerebellar disease have anti-Hu
antibodies (Shams’ili et al., 2003).
There are several other examples of paraneoplastic syn-
dromes involving the central nervous system including stiff
person syndrome, where the immune response is directed to
glutamic acid decarboxylase and to amphiphysin, resulting in
some circumstances in both Type 1 diabetes mellitus and
extreme stiffness of skeletal musclature (Darnell and Posner,
2006). The paraneoplastic syndromes exemplify the remarkable
relationships between antigens found on cancer and shared with
structures in specific anatomic locations of the nervous system.
In addition to cerebellar syndromes and stiff person syndromes,
there are examples of myelopathies, motor neuron disease,
encephalomyelitis, and limbic encephalitis, all representing dif-
ferent paraneoplastic syndromes.
To date, there are no animal models where a cancer is induced
that leads to a neurological syndrome. In fact, good autoimmune
models of paraneoplastic phenotypes in the CNS are nonexis-
tent (Darnell and Posner, 2003). There are some mouse models
where phenotypes are shared with human paraneoplastic
syndromes, including a ‘‘rolling mouse’’ with a with a R1262G
mutation in the alpha-1 subunit of the P/Q-type (Ca(v)2.1)
calcium channel that has manifestations including leg weakness
characteristic of Lambert Eaton syndrome (Molenaar, 2008).
However, this model of Lambert Eaton is not induced with auto-
immunity. Another mouse model induced via immunization with
this channel was described in a small group of rats, who devel-
oped weakness, but over the years there has been a lack of
follow on publications (Komai et al., 1999). Such models of para-
neoplastic syndromes, with both cancer and autoimmunity,
would allow one to test whether the autoimmune response to
the cancer, with its unwanted consequences in the nervous
system, is actually a consequence of effective tumor surveil-
lance. But to date, there are no goodmodels of the paraneoplas-
tic syndromes, akin to the models of MS with EAE, or transgenic
models of AD, induced with overexpressed beta amyloid.
There is some anecdotal evidence suggesting that treatment
of the autoimmune disease with immune suppression leads to
worsening of the tumor. Such studies, however, are not defini-
tive. For paraneoplastic disease and the underlying cancer,
neuro-oncologists recommend immune suppression to relieve
the symptoms of the autoimmune disease in the nervous system,
while also treating the cancer. Cancer therapy would include an
optimal regimen with surgical intervention, if warranted, chemo-130 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.therapy, if possible, and radiation therapy, when amenable
(Darnell and Posner, 2003). The field is clearly fascinating. We
are learning that such syndromes are not oddities and may
some day be amenable to interventions that alleviate both the
burden of the tumor and the consequences of autoimmunity
targeting the nervous system.
A Discipline ‘‘Comes of Age’’: Neuroimmunology
Research inneurobiologyand immunologyhasachievedacertain
confluence. Many of the key molecules in one system have been
shown to play starring roles in the other system. Though the
molecules are identical, in different contexts they take on new
and unexpected roles. In this review, the matter of molecules
having different roles in the nervous system and in the immune
system has been exemplified with discussions of the Toll recep-
tors, the inflammosome, the histocompatibility complex, the
complement cascade, aB crystallin, and GABA. We realize that
ancient defense systems in plants used these same molecules.
Plants defend themselves with molecules with homology to
Toll, to alpha B crystallin, and to IL-1beta. Plants employ all the
components of the GABA biochemical pathway in their response
to various stresses including heat stress. All this illuminates the
interrelations between biological systems.
The immune system and the nervous system are remarkable
ensembles that are at once sensors of impending danger and
responders to those dangers. These systems muster a remark-
able array of solutions and in many cases employ the very
same molecules to solve widely divergent problems. Both
systems have memory and remarkable specificity.
A key lesson in all these examples is that one should not
become overly worried when encountering a molecule in
a system, where its presence is largely unknown. Just because
a molecule is well known to one system does not mean it does
not have an amazing though different role in another system
(Table 1). One of the modern problems with ‘‘informatics’’ is
that it informs us of what we know and excludes what we do
not. Lists of ‘‘immune molecules’’ or ‘‘neurobiological mole-
cules’’ and ‘‘pathway analyses’’ are recipes for stereotypic
thinking. ‘‘Immuno’’-centricity and ‘‘neuro’’-centricity should be
shunned. We must look at the boundaries of the fields of neuro-
biology and immunology with a healthy dose of skepticism. In
many cases, plants already employed the molecules we now
study in the brain and in the immune system. The synthesis of
neurobiology and immunology in neuroimmunology is coming
of age, aided by input from the whole world of biology.
Table 1. Comparative Roles of Molecules in the Nervous System
and the Immune System
Neurobiology Immunology
Complement Eliminate synapses Opsonize bacteria,
destroy brain structures
MHC Modulate plasticity Present antigen to T cells
GABA Inhibitory
neurotransmitter
Inhibit inflammation
Alpha B Crystallin Lens protein, refract
light, provide immune
privilege
Inhibit inflammation
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